19.07.2012 - On the Iberian Peninsula opposition against the drastic budget cuts is forming. Big pharma is not immune from the cuts.
The Spanish R&D budget for 2012 has been slashed to 75% of last year’s value. Although the Spanish secretary of state for research, Carmen Vela, defends the plan saying that the „system is oversized and Spanish science could do more with less“, the affected sector howls in disagreement. „Excellence costs money and we will not reach it by shrinking investment“, says Carlos Andradas. Andradas is the president of the Confederation of Spanish Scientific Societies (COSCE). Together with other reputable science organisations in the country, COSCE demands the European Parliament to take action. In a letter sent to European Parliamentarians at the beginning of June, the Spanish scientists draw a comparison to Europe’s power in the economy: „The European Union is issuing recommendations on economic matters that governments take very seriously. We would like to hear recommendations on R&D spending as well“, says Andrades. So far no reactions from Strasbourg have been noted.
Portuguese healthcare is contending with different weapons. Last week, doctors and nurses went on a two-day workout with only emergency services left unaffected. The government’s actions to shrink its budget deficit threaten the quality of the healthcare system, say the unions. Reformers seem to get caught in crossfire as international pharma and chemistry businesses also raise the pressure. Merck KGAA from Darmstadt (Germany) warned the Portuguese government on 9 July that planned research projects worth €2m could be cancelled if the hospitals do not stick to the settlements regarding the liquidation of debts. According to information from the German newspaper FTD, the Portuguese hospitals alone owe the pharma industry about €1.5bn. Companies have to wait on average 550 days until their bills are cleared.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs. more